Lymphoma
Conditions
Keywords
stage I grade 3 follicular lymphoma, stage I adult diffuse large cell lymphoma, stage III grade 3 follicular lymphoma, stage III adult diffuse large cell lymphoma, stage IV grade 3 follicular lymphoma, stage IV adult diffuse large cell lymphoma, stage I mantle cell lymphoma, contiguous stage II grade 3 follicular lymphoma, contiguous stage II mantle cell lymphoma, contiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II grade 3 follicular lymphoma, noncontiguous stage II mantle cell lymphoma, noncontiguous stage II adult diffuse large cell lymphoma, stage III mantle cell lymphoma, stage IV mantle cell lymphoma
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. It is not yet known if combination chemotherapy plus filgrastim is more effective with or without rituximab in treating non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to determine the effectiveness of combination chemotherapy plus filgrastim with or without rituximab in treating older patients who have non-Hodgkin's lymphoma.
Detailed description
OBJECTIVES: * Compare the efficacy of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), and filgrastim (G-CSF) with or without rituximab on event-free survival of elderly patients with intermediate or high-risk non-Hodgkin's lymphoma. * Compare the complete remission rate, overall survival, and disease-free survival of patients treated with these regimens. * Compare the toxicity of these regimens in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, WHO classification, and International Prognostic Index score. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5; and filgrastim (G-CSF) subcutaneously on days 1-14. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. * Arm II: Patients receive cyclophosphamide, doxorubicin, vincristine, prednisone, and G-CSF as in arm I. Patients also receive rituximab IV on day 3 of courses 1-2 and on day 1 of courses 3-6 for a total of 6 doses. Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 400 patients (200 per treatment arm) will be accrued for this study within 5 years.
Interventions
BIOLOGICALfilgrastim
BIOLOGICALrituximab
DRUGcyclophosphamide
DRUGdoxorubicin hydrochloride
DRUGprednisone
DRUGvincristine sulfate
Sponsors
Commissie Voor Klinisch Toegepast Onderzoek
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed non-Hodgkin's lymphoma (NHL) * Low- or high-intermediate or high-risk lymphoma of any of the following subtypes: * Mantle cell lymphoma * Follicular lymphoma (grade III) * Diffuse large B-cell lymphoma * CD20-positive * No suspected or documented CNS involvement by NHL NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age: * 65 and over Performance status: * WHO 0-2 Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Bilirubin less than 1.75 mg/dL\* * Transaminases less than 2.5 times normal\* NOTE: \* Unless due to NHL Renal: * Creatinine less than 1.7 mg/dL (unless due to NHL) Cardiovascular: * No severe cardiac dysfunction * No New York Heart Association class II-IV heart disease * LVEF at least 45% Pulmonary: * No uncontrolled asthma requiring steroid treatment Other: * HIV negative * No intolerance to exogenous protein administration * No active, uncontrolled infection * No uncontrolled allergy requiring steroid treatment * No other malignancy within the past 5 years except basal cell skin cancer or stage 0 cervical cancer PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior immunotherapy for NHL Chemotherapy: * No prior chemotherapy for NHL Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy for NHL except local radiotherapy for potential organ dysfunction by localized lymphoma mass or infiltration * Concurrent local radiotherapy for potential or actual organ dysfunction by localized lymphoma mass or infiltration allowed Surgery: * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response | — |
| Overall survival | — |
| Disease-free interval | — |
| Toxicity | — |
Countries
Netherlands
Outcome results
None listed